Orenitram® (treprostinil) – Expanded indication
October 21, 2019 - United Therapeutics announced the FDA approval of Orenitram (treprostinil), for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) to delay disease progression and to improve exercise capacity.
Download PDF
